Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-SNA006
- Development stage
- Phase 2
- Lead developer
- SmartNuclide
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-SNA006 is a radiopharmaceutical compound used for positron emission tomography (PET) imaging to quantify CD8 expression in vivo. It consists of a nanobody (SNA006) site-specifically conjugated with the chelator NODAGA and radiolabeled with gallium-68. The drug binds specifically to CD8+ T cells, enabling noninvasive visualization and quantification of tumor-infiltrating CD8+ T lymphocytes in patients with solid tumors. This allows dynamic tracking of immune responses during cancer immunotherapy and may help guide individualized treatment strategies. Clinical studies have shown that it is well tolerated, exhibits rapid clearance from circulation, and provides high-quality imaging correlating with histological CD8 expression[1][2][3][4][5].
- Other names
- [68Ga]Ga-NODAGA-SNA006
02
Targets
CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on 68Ga-NODAGA-SNA006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-SNA006.